Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression-Reference-Cited by-同舟云学术

Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression

Published:2018-01-16 Issue:2 Volume:128 Page:644-654
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Hossain Dewan Md Sakib,Javaid Sarah,Cai Mingmei,Zhang Chunsheng,Sawant Anandi,Hinton Marlene,Sathe Manjiri,Grein Jeff,Blumenschein Wendy,Pinheiro Elaine M.,Chackerian Alissa

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/94586/files/pdf

Reference84 articles.

1. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

2. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

3. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

4. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

5. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy;Biomaterials;2025-02

2. Synthesis and immunotherapy efficacy of a PD-L1 small-molecule inhibitor combined with its 131I-iodide labelled isostructural compound;Bioorganic Chemistry;2024-12

3. Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases;International Immunopharmacology;2024-09

4. Immunogenic cell death inducers for cancer therapy: An emerging focus on natural products;Phytomedicine;2024-09

5. Endoplasmic reticulum-targeted delivery of celastrol and PD-L1 siRNA for reinforcing immunogenic cell death and potentiating cancer immunotherapy;Acta Pharmaceutica Sinica B;2024-08